A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nacresertib Moves Through the Body In Healthy Adult Japanese Participants

Part of paid clinical trials in Anaheim, California.

Sponsor
AbbVie
Study ID
NCT07600762
Phase
PHASE1
Status
Completed

Conditions

  • Healthy Volunteer

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • Nacresertib — DRUG
    Oral tablet
  • Placebo for Nacresertib — DRUG
    Oral tablet

Study Details

A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nacresertib Moves Through the Body In Healthy Adult Japanese Participants

Key Dates

First listed
May 22, 2026
Start date
Apr 21, 2026
Status verified
Jul 2026
Primary completion
Jun 17, 2026
Completion
Jun 17, 2026

Study Design

Enrollment
12 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Nacresertib
    Participants will receive a single dose of Nacresertib
  • Placebo Comparator: Placebo for Nacresertib
    Participants will receive a single dose of Placebo for Nacresertib

Primary Outcome Measure

Maximum Observed Plasma Concentration (Cmax) of Nacresertib [ Time Frame: Up to 9 Days ]

Locations (1)

FacilityCityStateZIPSite coordinators
CenExel ACT- Anaheim Clinical Trials /ID# 282482AnaheimCalifornia92801-

Find similar trials in Anaheim, CA

By research site
CenExel ACT- Anaheim Clinical Trials· Anaheim, CA

Related Studies